Anti-tumor activity was assessed in the B16-F10 syngeneic tumor model utilizing a small molecule antagonist of CXCR2, MK-7123 (Navarixin) and an anti-mouse PD-1 blocking antibody, muDX400. The gene discussed is CXCR2; the disease is neoplasm.